IGC

IGC Pharma, Inc. (IGC) ESG Analysis Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.8 (Moderate)

IGC’s R&D intensity versus revenue suggests some product-development focus, but peers with more mature sustainability disclosure typically provide clearer environmental accountability.

Low leverage reduces balance-sheet pressure that can constrain environmental investment, yet it does not by itself indicate stronger emissions, resource, or compliance management versus peers.

The absence of provided emissions, energy, or waste metrics limits evidence of environmental leadership, leaving IGC broadly in line with smaller-cap peers that also disclose sparsely.

Compared with better-disclosing peers, IGC appears neither structurally advantaged nor clearly disadvantaged on environmental oversight, because available data are too limited to show differentiated controls.

Social

Score:

Stock-based compensation at 1.7% of revenue implies some employee-alignment cost, but peers with stronger social positioning usually disclose broader workforce, safety, and retention metrics.

Limited disclosure on labor practices, diversity, training, and customer impacts weakens comparability, which keeps IGC below peers that report more complete social governance indicators.

The company’s modest capital structure may support continuity for stakeholders, yet that financial flexibility is not a direct social advantage without evidence of workforce or community programs.

Relative to peers, IGC’s social profile appears average to slightly weak because the available metrics show compensation discipline but not broader human-capital strength.

Governance

Score:

Debt-to-equity of 0.18 and negative net debt to EBITDA indicate restrained leverage, which generally lowers creditor pressure and supports governance flexibility versus more levered peers.

R&D at 5.1% of revenue suggests ongoing capital allocation to development, but peers with stronger governance typically pair such spending with clearer board oversight and disclosure.

Stock-based compensation at 1.7% of revenue is manageable, yet peers with stronger governance often provide more transparent dilution controls and executive pay alignment.

Overall governance appears modestly better than highly levered micro-cap peers, but limited disclosure on board structure, controls, and shareholder rights prevents a stronger relative score.

Overall Score

Score:

IGC’s ESG positioning is moderate versus peers because limited disclosure is partly offset by conservative leverage and manageable compensation intensity.

Score Driver: Limited ESG Disclosure Relative To Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on IGC Pharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →